Biopharma Microbiology Analyst I

Eurofins; Toronto; On-site; CAD 52,000 - 72,000; Full time

Benefits offered by this job

Health and dental coverage

Life and disability insurance

RRSP with 3% company match

Paid holidays

Paid time off

Job summary

A leading bioanalytics company is seeking a Microbiologist in Toronto, Ontario to perform microbiology testing on Biopharma samples. Responsibilities include conducting various microbiological analyses, maintaining accurate records, and ensuring compliance with quality and regulatory standards. Ideal candidates should have strong technical skills in lab procedures, experience with RNA/DNA extractions, and proficiency in MS Office. This role promises competitive benefits and requires relocation to Mississauga by 2026.

Qualifications

• Competent technical laboratory skills not requiring constant direct supervision.
• Ability to handle all kinds of Biopharma samples, including potentially cytotoxic materials.
• Familiar with instrumentation/equipment handling.

Responsibilities

• Perform microbiology testing on Biopharma samples.
• Maintain a neat and accurate record system of work performed.
• Ensure sample turnaround time goals are met.

Skills

General microbiology techniques

Good computer skills - proficiency with MS Office

Experience in RNA and DNA extractions

Experience in PCR technologies

Strong computer and organizational skills

Clear verbal and written communication skills

Tools

Laboratory Information Management Systems (LIMS)

Job description

A leading bioanalytics company is seeking a Microbiologist in Toronto, Ontario to perform microbiology testing on Biopharma samples. Responsibilities include conducting various microbiological analyses, maintaining accurate records, and ensuring compliance with quality and regulatory standards. Ideal candidates should have strong technical skills in lab procedures, experience with RNA/DNA extractions, and proficiency in MS Office. This role promises competitive benefits and requires relocation to Mississauga by 2026.